Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1759

1.

Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.

Nakamoto H, Mimura T, Honda N.

Hemodial Int. 2008 Oct;12 Suppl 2:S9-S14. doi: 10.1111/j.1542-4758.2008.00317.x.

PMID:
18837771
2.

Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.

Li H, Wang SX.

Blood Purif. 2008;26(2):151-6. doi: 10.1159/000113529. Epub 2008 Jan 22.

PMID:
18212498
3.

Recombinant human erythropoietin treatment of anemia in renal transplant patients.

Lezaic V, Djukanovic L, Pavlovic-Kentera V.

Ren Fail. 1995 Nov;17(6):705-14.

PMID:
8771243
4.

Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.

Movilli E, Cancarini GC, Zani R, Camerini C, Sandrini M, Maiorca R.

Nephrol Dial Transplant. 2001 Jan;16(1):111-4.

PMID:
11209002
5.

Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.

Attallah N, Osman-Malik Y, Frinak S, Besarab A.

Am J Kidney Dis. 2006 Apr;47(4):644-54.

PMID:
16564942
6.
7.

Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial.

Brimble KS, Rabbat CG, McKenna P, Lambert K, Carlisle EJ.

J Am Soc Nephrol. 2003 Oct;14(10):2654-61.

8.

Management of anemia in erythropoietin-resistant hemodialysis patients.

Dar Santos AE, Shalansky KF, Jastrzebski JP.

Ann Pharmacother. 2003 Dec;37(12):1768-73.

PMID:
14632604
9.

2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.

Gejyo F, Saito A, Akizawa T, Akiba T, Sakai T, Suzuki M, Nishi S, Tsubakihara Y, Hirakata H, Bessho M; Japanese Society for Dialysis Therapy.

Ther Apher Dial. 2004 Dec;8(6):443-59.

PMID:
15663544
10.

Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.

Allegra V, Martimbianco L, Vasile A.

Nephrol Dial Transplant. 1997 May;12(5):924-32.

PMID:
9175044
11.

[Comparative study of the efficacy of different regimens of intermittent subcutaneous dosing of erythropoietin beta in treatment of renal anemia in chronic dialysis patients].

Nesić V, Ostrić V, Kovacević Z, Dimković N, Curić S, Lazarević M, Ratković M, Bogdanović J, Jelacić R.

Med Pregl. 2005 May-Jun;58(5-6):279-85. Serbian.

PMID:
16526235
12.
13.

[Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].

Di Iorio B, Guastaferro P, Gironda A, Marano V, Morrongiello L, Cillo N, Zito B, Nigro F, Frieri A, Rubino R, Bellizzi V.

G Ital Nefrol. 2002 Sep-Oct;19(5):552-9. Italian.

PMID:
12439845
14.
15.

Melatonin prevents oxidative stress resulting from iron and erythropoietin administration.

Herrera J, Nava M, Romero F, Rodríguez-Iturbe B.

Am J Kidney Dis. 2001 Apr;37(4):750-7.

PMID:
11273875
16.

Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.

Giancaspro V, Nuzziello M, Pallotta G, Sacchetti A, Petrarulo F.

J Nephrol. 2000 Nov-Dec;13(6):444-9.

PMID:
11132761
17.

The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.

Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC; BA 16528 Study Investigators.

Clin Nephrol. 2007 May;67(5):306-17.

PMID:
17542340
18.
20.

Anemia and carnitine supplementation in hemodialyzed patients.

Kletzmayr J, Mayer G, Legenstein E, Heinz-Peer G, Leitha T, Hörl WH, Kovarik J.

Kidney Int Suppl. 1999 Mar;69:S93-106.

PMID:
10084293

Supplemental Content

Support Center